When does a branded drug maker have to turn over product samples to generic competitors? An antitrust battle between Actelion Pharmaceuticals and three of its generic rivals offered some clues, but the case settled Friday without providing a definitive answer.
March 03, 2014 at 03:27 PM
1 minute read
When is a branded drug maker obligated to turn over product samples to competitors working to develop cheaper generic versions?
A test of that question—an antitrust battle between Actelion Pharmaceuticals Ltd. and three of its generic rivals—settled on Friday without offering a definitive answer. But given the timing of the settlement and the history of the case, the obstacles appear steep for branded drug makers looking to keep their samples under wraps.
Presented by BigVoodoo
Join General Counsel and Senior Legal Leaders at the Premier Forum Designed For and by General Counsel from Fortune 1000 Companies
This conference brings together the industry's most influential & knowledgeable real estate executives from the net lease sector.
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Duane Morris LLP seeks a highly motivated junior associate to join its dynamic and growing Labor and Employment Class Action group in Chicag...
Duane Morris LLP seeks a full-time staff litigation attorney who has practiced between 3-5 years. Experience will include drafting motions, ...
Duane Morris LLP has an immediate opening for a senior level, highly motivated litigation associate to join its dynamic and growing Employme...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
